Address
Alexandria Real Estate Equities Inc
385 E Colorado Blvd
Suite 299
Pasadena, CA 91101
United States
Phone
Email
Website
Recent investment activity
KANDO id: 30642
Corporate information
Official name
Alexandria Real Estate Equities Inc
Registration country
Official identities
US CIK 0001035443
Funding rounds
Top investment portfolio themes
nanotechnology (2)
Investment activity status
Active investor
Selected investments
Displaying 1 - 17 of 17Company | Profile | Country | Date Sort descending | Funding | ||
---|---|---|---|---|---|---|
VLST Corp | N/A | |||||
MAP Pharmaceuticals Inc | Proprietary inhalation technologies to enhance the therapeutic benefits and commercial attractiveness of proven drugs. | N/A | ||||
Magen BioSciences Inc | N/A | |||||
Genocea Biosciences Inc | N/A | |||||
Concert Pharmaceuticals Inc | A biotechnology company creating new medicines through a novel scientific approach utilizing the naturally-occurring element deuterium. | N/A | ||||
MiddleBrook Pharmaceuticals Inc | A pharmaceutical company engages in the development and commercialization of anti-infective drug products. | N/A | ||||
Nanosys Inc | Nanotechnology-enabled systems | N/A | ||||
BioRelix Inc | Advanced fight against drug resistant microbes by attacking novel targets with novel drugs. | Seed Initial investment | ||||
MacroGenics Inc | Biotechnology company that develops immunotherapeutics to treat autoimmune disorders, cancer and infectious diseases. | N/A | ||||
Sirtris Pharmaceuticals Inc | Series C | |||||
BioRelix Inc | Advanced fight against drug resistant microbes by attacking novel targets with novel drugs. | Series A Follow-on investment | ||||
Cerulean Pharma Inc | Series B | |||||
BrainCells Inc | A neurogenesis-based drug discovery and development company targeting novel therapies for mood disorders and other central nervous system diseases. | Series B | ||||
Cambrios Technologies Corp (Cambrios Advanced Materials) | Developer of proprietary nanostructured electronic materials for the display industry | Series D Initial investment | ||||
Metabolon Inc | Provider of biomarker discovery and analysis | Series C | ||||
Theraclone Sciences Inc | N/A | |||||
Theraclone Sciences Inc | Series B |